Astellas Pharma

Incorporated in 2005, Astellas Pharma is a pharmaceutical company with its headquarters in Tokyo, Japan. The company operates in a variety of business segments including Transplantation, Urology, Oncology, Neuroscience, Infectious Diseases, Immunology, Diabetes and Metabolic Diseases, Cardiovascular, and Regenerative Medicine. Astellas Pharma is recognized for key brands such as Prograf (tacrolimus), an immunosuppressant prescribed for organ transplantation; Xtandi (enzalutamide), used in treating prostate cancer; and Vesicare (solifenacin) along with Betanis/Myrbetriq/Betmiga (mirabegron), both of which address overactive bladder conditions. The company's products and services have a broad international reach, being sold in various key markets across the United States, Japan, Europe, Asia, and other global regions, either through direct sales or partnerships. (Powered by AI)